Avisa Diagnostics Inc. (CNQ: AVBT.CN) Stock Competitors & Peer Comparison

Avisa Diagnostics Inc. (CNQ: AVBT.CN) plays a significant role within the Healthcare sector. Its performance on the CNQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AVBT.CN stands at 123.7K. In comparison, VMD.TO has a market cap of 402.2M. Regarding current trading prices, AVBT.CN is priced at CA$0.05 on the CNQ, while VMD.TO trades at CA$10.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AVBT.CN currently has a P/E ratio of -0.20, whereas VMD.TO's P/E ratio is 32.66. In terms of profitability, AVBT.CN's ROE is +4.09%, compared to VMD.TO's ROE of +0.06%. Regarding short-term risk, AVBT.CN is less volatile compared to VMD.TO. This indicates lower risk in terms of short-term price fluctuations for AVBT.CN.Check VMD.TO's competition here

Avisa Diagnostics Inc. (CNQ: AVBT.CN) plays a significant role within the Healthcare sector. Its performance on the CNQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AVBT.CN stands at 123.7K. In comparison, PRN.TO has a market cap of 338.7M. Regarding current trading prices, AVBT.CN is priced at CA$0.05 on the CNQ, while PRN.TO trades at CA$9.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AVBT.CN currently has a P/E ratio of -0.20, whereas PRN.TO's P/E ratio is -6.85. In terms of profitability, AVBT.CN's ROE is +4.09%, compared to PRN.TO's ROE of -0.62%. Regarding short-term risk, AVBT.CN is less volatile compared to PRN.TO. This indicates lower risk in terms of short-term price fluctuations for AVBT.CN.Check PRN.TO's competition here

Avisa Diagnostics Inc. (CNQ: AVBT.CN) plays a significant role within the Healthcare sector. Its performance on the CNQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AVBT.CN stands at 123.7K. In comparison, QIPT.TO has a market cap of 221.4M. Regarding current trading prices, AVBT.CN is priced at CA$0.05 on the CNQ, while QIPT.TO trades at CA$4.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AVBT.CN currently has a P/E ratio of -0.20, whereas QIPT.TO's P/E ratio is -15.56. In terms of profitability, AVBT.CN's ROE is +4.09%, compared to QIPT.TO's ROE of -0.10%. Regarding short-term risk, AVBT.CN is less volatile compared to QIPT.TO. This indicates lower risk in terms of short-term price fluctuations for AVBT.CN.Check QIPT.TO's competition here

Avisa Diagnostics Inc. (CNQ: AVBT.CN) plays a significant role within the Healthcare sector. Its performance on the CNQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AVBT.CN stands at 123.7K. In comparison, TMD.TO has a market cap of 128.3M. Regarding current trading prices, AVBT.CN is priced at CA$0.05 on the CNQ, while TMD.TO trades at CA$1.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AVBT.CN currently has a P/E ratio of -0.20, whereas TMD.TO's P/E ratio is -0.65. In terms of profitability, AVBT.CN's ROE is +4.09%, compared to TMD.TO's ROE of +8.58%. Regarding short-term risk, AVBT.CN is less volatile compared to TMD.TO. This indicates lower risk in terms of short-term price fluctuations for AVBT.CN.Check TMD.TO's competition here

Avisa Diagnostics Inc. (CNQ: AVBT.CN) plays a significant role within the Healthcare sector. Its performance on the CNQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AVBT.CN stands at 123.7K. In comparison, NVCN.TO has a market cap of 110.8M. Regarding current trading prices, AVBT.CN is priced at CA$0.05 on the CNQ, while NVCN.TO trades at CA$40.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AVBT.CN currently has a P/E ratio of -0.20, whereas NVCN.TO's P/E ratio is -1.96. In terms of profitability, AVBT.CN's ROE is +4.09%, compared to NVCN.TO's ROE of -1.21%. Regarding short-term risk, AVBT.CN is less volatile compared to NVCN.TO. This indicates lower risk in terms of short-term price fluctuations for AVBT.CN.Check NVCN.TO's competition here

Avisa Diagnostics Inc. (CNQ: AVBT.CN) plays a significant role within the Healthcare sector. Its performance on the CNQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AVBT.CN stands at 123.7K. In comparison, ATE.TO has a market cap of 15.6M. Regarding current trading prices, AVBT.CN is priced at CA$0.05 on the CNQ, while ATE.TO trades at CA$0.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AVBT.CN currently has a P/E ratio of -0.20, whereas ATE.TO's P/E ratio is -0.84. In terms of profitability, AVBT.CN's ROE is +4.09%, compared to ATE.TO's ROE of -0.40%. Regarding short-term risk, AVBT.CN is less volatile compared to ATE.TO. This indicates lower risk in terms of short-term price fluctuations for AVBT.CN.Check ATE.TO's competition here

Avisa Diagnostics Inc. (CNQ: AVBT.CN) plays a significant role within the Healthcare sector. Its performance on the CNQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AVBT.CN stands at 123.7K. In comparison, PMED.CN has a market cap of 11.4M. Regarding current trading prices, AVBT.CN is priced at CA$0.05 on the CNQ, while PMED.CN trades at CA$0.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AVBT.CN currently has a P/E ratio of -0.20, whereas PMED.CN's P/E ratio is -2.75. In terms of profitability, AVBT.CN's ROE is +4.09%, compared to PMED.CN's ROE of +0.93%. Regarding short-term risk, AVBT.CN is similarly volatile compared to PMED.CN. This indicates similar risk in terms of short-term price fluctuations for AVBT.CN.Check PMED.CN's competition here

Avisa Diagnostics Inc. (CNQ: AVBT.CN) plays a significant role within the Healthcare sector. Its performance on the CNQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AVBT.CN stands at 123.7K. In comparison, ASTI.CN has a market cap of 552K. Regarding current trading prices, AVBT.CN is priced at CA$0.05 on the CNQ, while ASTI.CN trades at CA$0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AVBT.CN currently has a P/E ratio of -0.20, whereas ASTI.CN's P/E ratio is -0.86. In terms of profitability, AVBT.CN's ROE is +4.09%, compared to ASTI.CN's ROE of +0.11%. Regarding short-term risk, AVBT.CN is similarly volatile compared to ASTI.CN. This indicates similar risk in terms of short-term price fluctuations for AVBT.CN.Check ASTI.CN's competition here

Avisa Diagnostics Inc. (CNQ: AVBT.CN) plays a significant role within the Healthcare sector. Its performance on the CNQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AVBT.CN stands at 123.7K. In comparison, IME.CN has a market cap of 162.5K. Regarding current trading prices, AVBT.CN is priced at CA$0.05 on the CNQ, while IME.CN trades at CA$0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AVBT.CN currently has a P/E ratio of -0.20, whereas IME.CN's P/E ratio is -0.04. In terms of profitability, AVBT.CN's ROE is +4.09%, compared to IME.CN's ROE of +0.20%. Regarding short-term risk, AVBT.CN is similarly volatile compared to IME.CN. This indicates similar risk in terms of short-term price fluctuations for AVBT.CN.Check IME.CN's competition here

Avisa Diagnostics Inc. (CNQ: AVBT.CN) plays a significant role within the Healthcare sector. Its performance on the CNQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AVBT.CN stands at 123.7K. In comparison, MYTC.CN has a market cap of 159.4K. Regarding current trading prices, AVBT.CN is priced at CA$0.05 on the CNQ, while MYTC.CN trades at CA$0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AVBT.CN currently has a P/E ratio of -0.20, whereas MYTC.CN's P/E ratio is -0.08. In terms of profitability, AVBT.CN's ROE is +4.09%, compared to MYTC.CN's ROE of +0.60%. Regarding short-term risk, AVBT.CN is similarly volatile compared to MYTC.CN. This indicates similar risk in terms of short-term price fluctuations for AVBT.CN.Check MYTC.CN's competition here

Avisa Diagnostics Inc. (CNQ: AVBT.CN) plays a significant role within the Healthcare sector. Its performance on the CNQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AVBT.CN stands at 123.7K. In comparison, HSM.TO has a market cap of 0. Regarding current trading prices, AVBT.CN is priced at CA$0.05 on the CNQ, while HSM.TO trades at CA$18.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AVBT.CN currently has a P/E ratio of -0.20, whereas HSM.TO's P/E ratio is -1.73. In terms of profitability, AVBT.CN's ROE is +4.09%, compared to HSM.TO's ROE of -2.91%. Regarding short-term risk, AVBT.CN is less volatile compared to HSM.TO. This indicates lower risk in terms of short-term price fluctuations for AVBT.CN.Check HSM.TO's competition here